International Stem Cell Corp. (ISCO) Edges Ever Closer to First Real Therapeutic Solution for Halting & Even Reversing Parkinson’s
With the recent announcement from Australia’s version of the FDA, the Therapeutic Goods Administration, that pluripotent stem cell manufacturing innovator International Stem Cell Corp. (OTCQB: ISCO) has been cleared to start Phase I/IIa dose escalation clinical trials focused on the safety and efficacy of its human parthenogenetic neural stem cells (ISC-hpNSCs), the company has taken another major step toward a real therapeutic solution to Parkinson's disease. An incurable condition that primarily affects the planet’s growing elderly population, Parkinson's currently afflicts well over 10 million people worldwide and represents a therapeutics market somewhere in the neighborhood of $2.6 billion. However, while…